The dual PPAR-α/δ agonist elafibranor attenuates TGF-β 1 -induced cardiac fibrosis through redox-metabolic and bioenergetic reprogramming…

Verdict. Background Cardiac fibrosis drives adverse myocardial remodelling through persistent fibroblast activation, ECM deposition, and impaired cardiac function. It intersects mitochondrial stress/dysfunction themes (functional impairment; cell death; bioenergetics).

What the authors report

Current therapies offer limited protection against cardiac fibrosis progression. Elafibranor is a dual PPAR-α/δ agonist approved for the treatment of liver disease.

Key results stated in the abstract include the following. Background Cardiac fibrosis drives adverse myocardial remodelling through persistent fibroblast activation, ECM deposition, and impaired cardiac function. Results At non-cytotoxic concentrations, elafibranor attenuated TGF-β 1 -driven cardiac fibrosis responses. In 2D cardiac fibroblasts, it reduced myofibroblast differentiation, procollagen 1α1 secretion, and partially restored mitochondrial respiratory capacity.

Why it matters for mitochondrial biology

Within mitochondrial research, this work maps primarily to calcium signaling, apoptosis, redox biology, metabolism. It is relevant to mitochondrial dysfunction discourse because the abstract invokes functional impairment, cell death, bioenergetics, disease context. That does not by itself establish a validated disease mechanism; it indicates thematic proximity. Because a therapeutic or interventional angle is present, the piece is of interest for mitochondrial-targeted drug hypothesis generation—subject to full-text validation of endpoints and safety context. Server: biorxiv. Posted 2026-08-19. Synthesis confidence is bounded by abstract completeness.

Study design (abstract-level)

Background Cardiac fibrosis drives adverse myocardial remodelling through persistent fibroblast activation, ECM deposition, and impaired cardiac function. However, its effects in human models of cardiac fibrosis remain insufficiently explored. Methods Elafibranor was evaluated in complementary human in vitro TGF-β 1 -induced cardiac fibrosis models: 2D primary fibroblasts, 3D fibroblast spheroids, spontaneously contracting 3D cardiac microtissues, and hiPSC-derived cardiomyocytes.

Principal findings

1. Background Cardiac fibrosis drives adverse myocardial remodelling through persistent fibroblast activation, ECM deposition, and impaired cardiac function.
2. Results At non-cytotoxic concentrations, elafibranor attenuated TGF-β 1 -driven cardiac fibrosis responses.
3. In 2D cardiac fibroblasts, it reduced myofibroblast differentiation, procollagen 1α1 secretion, and partially restored mitochondrial respiratory capacity.
4. In 3D spheroids, it preserved viability, attenuated caspase-3/7 activation, and suppressed procollagen 1α1 release.
5. In cardiac microtissues, elafibranor reduced ECM accumulation, shifted transcriptomic profiles toward redox-metabolic/cytoprotective pathways, altered adenine nucleotide and NAD pools, and partially recovered contraction parameters.

Limitations of this brief

• This Mitos brief is an abstract-level synthesis of a preprint; it is not peer review and not a substitute for reading the full paper.
• Preprint status: findings may change with revision or journal review.
• Effect sizes, n numbers, statistics, and full experimental controls are typically incomplete at abstract resolution.
• Comparator/control language is weak or absent in the abstract, limiting causal inference from this brief alone.
• Primary source: biorxiv DOI 10.64898/2026.08.18.745425 (posted 2026-08-19).

Open scientific questions

• Which specific experimental panels in the full paper establish the strongest causal claim, and how robust are the controls?
• Are OXPHOS defects primary drivers or secondary consequences of broader cellular stress?
• What dose, timing, and off-target profile would be required to take the intervention seriously as a therapeutic hypothesis?
• How do these findings sit relative to prior literature on the same pathway—replication, contradiction, or incremental extension?

Bottom line

For mitochondrial biologists focused on calcium signaling, apoptosis, redox biology, this preprint is worth full-text review soon. Abstract-level takeaway: Background Cardiac fibrosis drives adverse myocardial remodelling through persistent fibroblast activation, ECM deposition, and impaired cardiac function. Confirm methods, effect sizes, and controls in the full PDF before citing the result as established.

Bibliographic record

Abstract-based editorial synthesis by Mitos. Not peer review.